Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Specific and off-target immune responses following COVID-19 vaccination with ChAdOx1-S and BNT162b2 vaccines-an exploratory sub-study of the BRACE trial.

Subjects: BNT162 Vaccine*/BNT162 Vaccine*/BNT162 Vaccine*/immunology ; BNT162 Vaccine*/BNT162 Vaccine*/BNT162 Vaccine*/administration & dosage ; COVID-19*/COVID-19*/COVID-19*/prevention & control

  • Source: EBioMedicine [EBioMedicine] 2024 May; Vol. 103, pp. 105100. Date of Electronic Publication: 2024 Apr 24.Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients.

  • Authors : Massa F; Department of Nephrology, Dialysis and Transplantation, Pasteur 2 Hospital, Nice University Hospital, 30 voie Romaine, 06300, Nice, France; Laboratory of Molecular Physio Medicine, University Côte d'Azur, CNRS, 28 Avenue de Valombrose, 06107, Nice, France

Subjects: Kidney Transplantation*; Antibodies, Neutralizing/Antibodies, Neutralizing/Antibodies, Neutralizing/*immunology ; BNT162 Vaccine/BNT162 Vaccine/BNT162 Vaccine/*immunology SARS-CoV-2 variants

  • Source: EBioMedicine [EBioMedicine] 2021 Nov; Vol. 73, pp. 103679. Date of Electronic Publication: 2021 Nov 08.Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.

  • Authors : Groß R; Institute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, Germany.; Zanoni M

Subjects: Immunization, Secondary*; Antibodies, Neutralizing/Antibodies, Neutralizing/Antibodies, Neutralizing/*immunology ; BNT162 Vaccine/BNT162 Vaccine/BNT162 Vaccine/*administration & dosage SARS-CoV-2 variants

  • Source: EBioMedicine [EBioMedicine] 2022 Jan; Vol. 75, pp. 103761. Date of Electronic Publication: 2021 Dec 17.Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers.

  • Authors : Moncunill G; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain; CIBER de Enfermedades Infecciosas, Madrid, Spain. Electronic address: .

Subjects: Health Personnel*; 2019-nCoV Vaccine mRNA-1273/2019-nCoV Vaccine mRNA-1273/2019-nCoV Vaccine mRNA-1273/*administration & dosage ; Antibody Formation/Antibody Formation/Antibody Formation/*drug effects

  • Source: EBioMedicine [EBioMedicine] 2022 Jan; Vol. 75, pp. 103805. Date of Electronic Publication: 2022 Jan 12.Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients.

  • Authors : Azzi L; Azienda Socio-Sanitaria Territoriale dei Sette Laghi, Department of Medicine and Surgery, University of Insubria, Varese, Italy. Electronic address: .; Dalla Gasperina D

Subjects: Immunization, Secondary*; Antibodies, Neutralizing/Antibodies, Neutralizing/Antibodies, Neutralizing/*immunology ; Antibodies, Viral/Antibodies, Viral/Antibodies, Viral/*immunology

  • Source: EBioMedicine [EBioMedicine] 2022 Jan; Vol. 75, pp. 103788. Date of Electronic Publication: 2021 Dec 23.Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Editorial & Opinion

What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?

  • Authors : Silvestris N; Medical Oncology Unit, IRCCS Istituto Tumori 'Giovanni Paolo II' of Bari, 70124 Bari, Italy; Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', 70124 Bari, Italy. Electronic address: .

Subjects: Immunity* ; Immunocompromised Host*; BNT162 Vaccine/BNT162 Vaccine/BNT162 Vaccine/*immunology

  • Source: EBioMedicine [EBioMedicine] 2021 Dec; Vol. 74, pp. 103733. Date of Electronic Publication: 2021 Dec 01.Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response.

  • Authors : Ontañón J; Immunology Unit, Albacete General Hospital, c/ Hermanos Falcó 37, E-02008 Albacete, Spain.; Blas J

Subjects: Immunity, Humoral*; BNT162 Vaccine/BNT162 Vaccine/BNT162 Vaccine/*immunology ; COVID-19/COVID-19/COVID-19/*pathology

  • Source: EBioMedicine [EBioMedicine] 2021 Nov; Vol. 73, pp. 103656. Date of Electronic Publication: 2021 Oct 30.Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Differences in SARS-CoV-2 specific humoral and cellular immune responses after contralateral and ipsilateral COVID-19 vaccination.

  • Authors : Ziegler L; Department of Transplant and Infection Immunology, Saarland University, Germany.; Klemis V

Subjects: COVID-19 Vaccines* ; COVID-19*/COVID-19*/COVID-19*/prevention & control; Humans

  • Source: EBioMedicine [EBioMedicine] 2023 Sep; Vol. 95, pp. 104743. Date of Electronic Publication: 2023 Aug 11.Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study.

  • Authors : Altarawneh HN; Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar

Subjects: COVID-19*/COVID-19*/COVID-19*/prevention & control ; Hepatitis D*; Humans SARS-CoV-2 variants

  • Source: EBioMedicine [EBioMedicine] 2023 Sep; Vol. 95, pp. 104734. Date of Electronic Publication: 2023 Jul 27.Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV - a prospective observational cohort study.

  • Authors : Heftdal LD; Viro-Immunology Research Unit, Department of Infectious Diseases, Section 8632, University of Copenhagen, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Oe, Denmark; Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Oe, Denmark

Subjects: COVID-19*/COVID-19*/COVID-19*/prevention & control ; HIV Infections*; Humans

  • Source: EBioMedicine [EBioMedicine] 2023 Jul; Vol. 93, pp. 104661. Date of Electronic Publication: 2023 Jun 16.Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
  • 1-10 of  37 results for ""BNT162 Vaccine""